---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115223"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:18:58.697042+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q3: DEXTENZA revenue up 26% YoY to $15M; net loss narrows to $0.5M

## Summary
- DEXTENZA net product revenue $15.0M (+26% vs Q3 2022), in line with Q2 2023; full-year guidance raised to upper end of $55-60M.
- Net loss improved to $(0.5M) or $(0.01) per basic share vs $(24.2M) loss in Q3 2022; diluted EPS $(0.25).
- FDA agreed under Special Protocol Assessment to pivotal SOL trial for AXPAXLI (wet AMD); first patient dosing expected by year-end.
- Cash and cash equivalents $110.6M as of Sept 30, 2023; management believes sufficient to fund operations into 2025.
- Top-line data from HELIOS trial (NPDR) expected Q2 2024; Phase 2 data for OTX-TIC (glaucoma) expected April 2024.

## SEC filing metadata
- accession: 0001104659-23-115223
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/0001104659-23-115223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/tm2329748d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115223
- JSON: https://secwatch.observer/filing/0001104659-23-115223.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115223.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported third quarter ended September 30, 2023 results: revenue $15.0 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $15.0 million
  - Result: reported results
  source text: Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early April 2024 DEXTENZA ® Net Product Revenue in Q3 2023 was $15.0 million, Representing Growth of Approximately 26% Over Q3 2022 BEDFORD, Mass.–(BUSINESS WIRE)— November 7, 2023 – Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/0001104659-23-115223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.